SCHEMBL1836769

SCHEMBL1836769

CCCCCCCCCCCCOC(=O)OC

nearest known ligand 0.61

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
EPHX1 P07099 1/20 0.61
NAAA Q02083 1/20 0.59
ACHE P22303 6/20 0.53
TSHR P16473 3/20 0.53
FAAH O00519 1/20 0.53
ZDHHC7 Q9NXF8 1/20 0.52
HCAR2 Q8TDS4 1/20 0.50
RAD52 P43351 1/20 0.50
NPSR1 Q6W5P4 1/20 0.50
ALDH1A1 P00352 2/20 0.48
LMNA P02545 1/20 0.48
DGKA P23743 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1840884 1.00 EPHX1 (0.61) EPHX1NAAAACHETSHRFAAH
SCHEMBL1837803 1.00 EPHX1 (0.61) EPHX1NAAAACHETSHRFAAH
SCHEMBL1840170 1.00 EPHX1 (0.61) EPHX1NAAAACHETSHRFAAH
SCHEMBL1833843 1.00 EPHX1 (0.61) EPHX1NAAAACHETSHRFAAH
SCHEMBL1833746 1.00 EPHX1 (0.61) EPHX1NAAAACHETSHRFAAH
SCHEMBL1839720 1.00 EPHX1 (0.61) EPHX1NAAAACHETSHRFAAH
SCHEMBL1837221 1.00 EPHX1 (0.61) EPHX1NAAAACHETSHRFAAH
SCHEMBL1835070 1.00 EPHX1 (0.61) EPHX1NAAAACHETSHRFAAH
SCHEMBL1835358 1.00 EPHX1 (0.61) EPHX1NAAAACHETSHRFAAH
SCHEMBL448774 1.00 EPHX1 (0.61) EPHX1NAAAACHETSHRFAAH

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3965765-A1 OPIOID RECEPTOR ANTAGONIST PRODRUGS Nirsum Laboratories, Inc. (US) 2022-03-16 EP claimed
US-10308587-B2 Functionalized fluoropolymers and electrolyte compositions Blue Current, Inc. (US) 2019-06-04 US claimed
US-10077231-B2 Functionalized fluoropolymers and electrolyte compositions Blue Current, Inc. (US) 2018-09-18 US claimed
US-9543619-B2 Functionalized phosphorus containing fluoropolymers and electrolyte compositions Blue Current, Inc. (US) 2017-01-10 US claimed
US-20160301107-A1 FUNCTIONALIZED PERFLUOROALKANES AND ELECTROLYTE COMPOSITIONS Blue Current, Inc. 2016-10-13 US claimed
WO-2016126737-A1 FUNCTIONALIZED FLUOROPOLYMERS AND ELECTROLYTE COMPOSITIONS Blue Current, Inc. (US) 2016-08-11 WO claimed
WO-2016126716-A1 FUNCTIONALIZED PHOSPHORUS CONTAINING FLUOROPOLYMERS AND ELECTROLYTE COMPOSITIONS Blue Current, Inc. (US) 2016-08-11 WO claimed
US-20160226103-A1 FUNCTIONALIZED FLUOROPOLYMERS AND ELECTROLYTE COMPOSITIONS Blue Current, Inc. 2016-08-04 US claimed
US-20160226104-A1 FUNCTIONALIZED PHOSPHORUS CONTAINING FLUOROPOLYMERS AND ELECTROLYTE COMPOSITIONS Blue Current, Inc. 2016-08-04 US claimed
US-20160226102-A1 FUNCTIONALIZED FLUOROPOLYMERS AND ELECTROLYTE COMPOSITIONS Blue Current, Inc. 2016-08-04 US claimed
CN-122055369-A Bridged tricyclic carbamoyl pyridone compounds and uses thereof 吉利德科学公司 2026-05-15 CN disclosed
US-12318403-B2 2′3′-cyclic dinucleotides and prodrugs thereof INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY ASCR, V.V.I. (CZ) 2025-06-03 US disclosed
CN-114126615-B Opioid receptor antagonist prodrugs 尼萨姆实验室公司 2024-12-31 CN disclosed
EP-4446310-A1 METHOD FOR PRODUCING BLOCKED ISOCYANATE COMPOUND AND METHOD FOR PRODUCING ISOCYANATE COMPOUND Asahi Kasei Kabushiki Kaisha (JP) 2024-10-16 EP disclosed
CN-118382612-A Method for producing blocked isocyanate compound and method for producing isocyanate compound 旭化成株式会社 2024-07-23 CN disclosed
US-7157442-B2 Antibacterial compound SANKYO COMPANY, LIMITED (JP) 2007-01-02 US disclosed
CN-1699328-A Process for preparing dialkyl carbonate UNIV EAST CHINA SCIENCE & TECH (CN) 2005-11-23 CN disclosed
EP-1209166-B1 NOVEL A-500359 DERIVATIVES SANKYO CO (JP) 2004-03-31 EP disclosed
US-20030171330-A1 Antibacterial compound SANKYO COMPANY, LIMITED (JP) 2003-09-11 US disclosed
EP-1209166-A1 NOVEL A-500359 DERIVATIVES Sankyo Company, Limited (JP) 2002-05-29 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10308587-B2 Functionalized fluoropolymers and electrolyte compositions PEF1, PFAS, PFKFB3 EPHX1 1076/4885NAAA 1146/4885ACHE 4089/4885
US-20030171330-A1 Antibacterial compound TLR1, MPO, O60361 EPHX1 3783/4885NAAA 1397/4885ACHE 3538/4885
US-12318403-B2 2′3′-cyclic dinucleotides and prodrugs thereof STING1, CGAS, NT5C2 EPHX1 1704/4885NAAA 1097/4885ACHE 2455/4885
US-10077231-B2 Functionalized fluoropolymers and electrolyte compositions PEF1, PFAS, PFKFB3 EPHX1 1076/4885NAAA 1146/4885ACHE 4089/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.